Serum LECT2 level as a prognostic indicator in acute liver failure

Area of Science:

• Hepatology
• Biochemistry
• Immunology

Background:

• Acute liver failure (ALF) is a critical condition with high mortality.
• Identifying reliable prognostic markers for ALF is crucial for patient management.
• Leukocyte cell-derived chemotaxin2 (LECT2) is a protein with potential roles in inflammation and tissue repair.

Purpose of the Study:

• To investigate the relationship between serum LECT2 levels and liver function in ALF patients.
• To evaluate the potential of serum LECT2 as a prognostic indicator for ALF recovery.
• To explore LECT2's role in hepatocyte regeneration following injury.

Main Methods:

• Retrospective analysis of six ALF patients admitted in 2002.
• Measurement of serum LECT2, GOT (glutamic-oxaloacetic transaminase), and GPT (glutamic-pyruvic transaminase) levels.
• Correlation analysis between LECT2 levels and liver function parameters (GOT, GPT), and patient outcomes.

Main Results:

• Serum LECT2 levels were inversely proportionate to GOT and GPT levels.
• The lowest serum LECT2 levels coincided with peak GPT levels.
• Serum LECT2 levels increased as liver function recovered.
• Maximum serum LECT2 levels were significantly lower in non-survivors compared to survivors (0.96 +/- 0.8 ng/mL vs 12.9 +/- 4.3 ng/mL).

Conclusions:

• Serum LECT2 levels may serve as a valuable prognostic indicator for recovery in acute liver failure.
• LECT2 appears to play a role in the regeneration process of hepatocytes after injury.
• Further research is warranted to elucidate the precise mechanisms of LECT2 in liver regeneration and its clinical utility.